Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biocompatibility Evaluation of Contact Lens Multipurpose Solutions Through Novel Genotoxicity Assays

Biocompatibility Evaluation of Contact Lens Multipurpose Solutions Through Novel Genotoxicity Assays AbstractIntroduction: Genotoxicity testing is necessary to address potential mutagenic characteristics of pharmaceutical candidates and medical devices depending on their intended use. Adapting such tests to contact lens multipurpose solutions (MPS) may be required due to their antimicrobial nature or to fulfill specific regulatory requirements. We describe a novel methodology for genotoxicity and biocompatibility evaluation of MPS in the context of traditional testing.Materials and Methods: Blink RevitaLens® Multipurpose Disinfecting Solution (MPDS) or contact lens (Acuvue® Advance and Acuvue® 2 brand) extracts were tested by Ames assay and Chromosome Aberration (ChrAb) Assays. A novel procedure for cycling contact lenses in MPDS was developed for testing. Before assays with the Blink RevitaLens MPDS disinfectant ingredient, Alexidine Dihydrochloride (ALX) was diluted for dose-range tests identifying TA100 or Chinese Hamster Ovary cytotoxicity levels to determine the amount of ALX appropriate for each assay.Results: MiniScreen Ames and Ames show Blink RevitaLens MPDS and the contact lens extracts did not increase the number of revertant colonies compared to saline, suggesting nonmutagenicity. The test articles also did not increase ChrAb, indicating they are nonclastogeneic. Below its cytotoxic limits, ALX did not increase the frequency of revertants in the Ames assay or demonstrate chromosome changes compared with controls.Discussion/Conclusions: Results from novel and standard genotoxicity assays demonstrated that Blink RevitaLens MPDS and ALX are not genotoxic or clastogenic. Novel cycling of contact lenses in MPDS is beneficial and accurate for biocompatibility testing on MPDS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied In Vitro Toxicology Mary Ann Liebert

Biocompatibility Evaluation of Contact Lens Multipurpose Solutions Through Novel Genotoxicity Assays

Applied In Vitro Toxicology , Volume 4 (1): 7 – Mar 1, 2018

Biocompatibility Evaluation of Contact Lens Multipurpose Solutions Through Novel Genotoxicity Assays

Applied In Vitro Toxicology , Volume 4 (1): 7 – Mar 1, 2018

Abstract

AbstractIntroduction: Genotoxicity testing is necessary to address potential mutagenic characteristics of pharmaceutical candidates and medical devices depending on their intended use. Adapting such tests to contact lens multipurpose solutions (MPS) may be required due to their antimicrobial nature or to fulfill specific regulatory requirements. We describe a novel methodology for genotoxicity and biocompatibility evaluation of MPS in the context of traditional testing.Materials and Methods: Blink RevitaLens® Multipurpose Disinfecting Solution (MPDS) or contact lens (Acuvue® Advance and Acuvue® 2 brand) extracts were tested by Ames assay and Chromosome Aberration (ChrAb) Assays. A novel procedure for cycling contact lenses in MPDS was developed for testing. Before assays with the Blink RevitaLens MPDS disinfectant ingredient, Alexidine Dihydrochloride (ALX) was diluted for dose-range tests identifying TA100 or Chinese Hamster Ovary cytotoxicity levels to determine the amount of ALX appropriate for each assay.Results: MiniScreen Ames and Ames show Blink RevitaLens MPDS and the contact lens extracts did not increase the number of revertant colonies compared to saline, suggesting nonmutagenicity. The test articles also did not increase ChrAb, indicating they are nonclastogeneic. Below its cytotoxic limits, ALX did not increase the frequency of revertants in the Ames assay or demonstrate chromosome changes compared with controls.Discussion/Conclusions: Results from novel and standard genotoxicity assays demonstrated that Blink RevitaLens MPDS and ALX are not genotoxic or clastogenic. Novel cycling of contact lenses in MPDS is beneficial and accurate for biocompatibility testing on MPDS.

Loading next page...
 
/lp/mary-ann-liebert/biocompatibility-evaluation-of-contact-lens-multipurpose-solutions-vvqENkRK0d
Publisher
Mary Ann Liebert
Copyright
Copyright 2018, Mary Ann Liebert, Inc.
ISSN
2332-1512
eISSN
2332-1539
DOI
10.1089/aivt.2017.0026
Publisher site
See Article on Publisher Site

Abstract

AbstractIntroduction: Genotoxicity testing is necessary to address potential mutagenic characteristics of pharmaceutical candidates and medical devices depending on their intended use. Adapting such tests to contact lens multipurpose solutions (MPS) may be required due to their antimicrobial nature or to fulfill specific regulatory requirements. We describe a novel methodology for genotoxicity and biocompatibility evaluation of MPS in the context of traditional testing.Materials and Methods: Blink RevitaLens® Multipurpose Disinfecting Solution (MPDS) or contact lens (Acuvue® Advance and Acuvue® 2 brand) extracts were tested by Ames assay and Chromosome Aberration (ChrAb) Assays. A novel procedure for cycling contact lenses in MPDS was developed for testing. Before assays with the Blink RevitaLens MPDS disinfectant ingredient, Alexidine Dihydrochloride (ALX) was diluted for dose-range tests identifying TA100 or Chinese Hamster Ovary cytotoxicity levels to determine the amount of ALX appropriate for each assay.Results: MiniScreen Ames and Ames show Blink RevitaLens MPDS and the contact lens extracts did not increase the number of revertant colonies compared to saline, suggesting nonmutagenicity. The test articles also did not increase ChrAb, indicating they are nonclastogeneic. Below its cytotoxic limits, ALX did not increase the frequency of revertants in the Ames assay or demonstrate chromosome changes compared with controls.Discussion/Conclusions: Results from novel and standard genotoxicity assays demonstrated that Blink RevitaLens MPDS and ALX are not genotoxic or clastogenic. Novel cycling of contact lenses in MPDS is beneficial and accurate for biocompatibility testing on MPDS.

Journal

Applied In Vitro ToxicologyMary Ann Liebert

Published: Mar 1, 2018

There are no references for this article.